lebrikizumab

This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.

Dermira craters as acne drug fails late-stage test

Also in its pipeline is an injectable drug for atopic dermatitis - I L-13 inhibitor lebrikizumab - which was developed by Roche and licensed to Dermira in a deal valued at up ... That programme is in mid-stage clinical testing. Even if it successfully

Latest news

Setback for AZ as tralokinumab flunks asthma trial

The failure of tralokinumab hasn’t come out of the blue, as another trial (STRATOS 1) also failed to hit the mark, and other IL-13 inhibitors - including Roche’s lebrikizumab
Roche out-licenses lebrikizumab rights to Dermira

Roche out-licenses lebrikizumab rights to Dermira. Swiss drug maker stands to receive $80m upfront for the drug. ... Roche has opted to out-license the bulk of the rights to its IL-13 inhibitor lebrikizumab to dermatology company Dermira in a deal valued
AZ trial adds to pessimism about anti-IL-13 asthma drugs

It looks increasingly like a lost cause as AZ already reported disappointing phase IIb data with tralokinumab, and last year Roche reported disappointing results with its anti-IL-13 candidate lebrikizumab,
Teva gets EU nod for severe asthma drug Cinqaero

13 inhibitor lebrikizumab.
Roche shares slip as profits miss expectations

Aside with atezolizumab, Roche is also looking ahead to possible launches for multiple sclerosis candidate ocrelizumab - also due for filing shortly - as well as asthma drug lebrikizumab.

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Pharma deals during August 2014

This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager: Competitive salary commensurate with experience

Home based, Chief Medical Writer, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Client Services Director – Healthcare Advertising - London: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Editorial Team Leader, Medical Communications: Excellent package

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Delivery Manager/ Head of Delivery – Executive Search: Neg

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Home based, Senior Medical Writer, Medical Communications: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Business Unit Head, Medical Communications, London: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Editorial Director – Medical Education (MedComms): Neg

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Client Services Director - Med Comms: Great salary and bebefits

Subscribe to our email news alerts

PMHub

Add my company

Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....